Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2003

Primary Completion Date

September 30, 2003

Conditions
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
DRUG

bortezomib

Trial Locations (15)

46601

CCOP - Northern Indiana CR Consortium, South Bend

49085

Oncology Care Associates, P.L.L.C., Saint Joseph

53226

Medical College of Wisconsin Cancer Center, Milwaukee

60201

CCOP - Evanston, Evanston

60426

Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

60637-1470

University of Chicago Cancer Research Center, Chicago

60153-5500

Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood

61615-7828

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

46885-5099

Fort Wayne Medical Oncology and Hematology, Fort Wayne

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

N6A 4L6

London Regional Cancer Program at London Health Sciences Centre, London

K1H 8L6

Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00066352 - Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | Biotech Hunter | Biotech Hunter